Randomized study of teriflunomide effects on immune responses to neoantigen and recall antigens.

ABSTRACT:

Objective

To evaluate immune responses to neoantigen and recall antigens in healthy subjects treated with teriflunomide.

Methods

This was a randomized, double-blind, placebo-controlled study. Subjects received oral teriflunomide (70 mg once daily for 5 days followed by 14 mg once daily for 25 days) or placebo for 30 days. Antibody responses were evaluated following rabies vaccination (neoantigen) applied at days 5, 12, and 31 of the treatment period. Occurrence of delayed-type hypersensitivity (DTH) to Candida albicans, Trichophyton, and tuberculin (recall antigens) was assessed before and at the end of treatment to investigate cellular memory response. Safety and pharmacokinetics were evaluated.

Results

Forty-six randomized subjects were treated (teriflunomide, n = 2

SUBMITTER: Bar-Or A 

PROVIDER: S-EPMC4335822 | biostudies-literature | 2015 Apr

REPOSITORIES: biostudies-literature